Oligo/asymptomatic participants* | Symptomatic participants† | Hospital admitted participants | |
N (%) | 17 (11) | 107 (71) | 25 (16) |
Male (%) | 11 (64) | 40 (37) | 20 (80) |
Age (median; p25, p75) | 42 (33–57) | 53 (39–59) | 56 (54–64) |
Clinical signs and symptoms | |||
Fever | 7 (44) | 94 (83) | 23 (92) |
Headache/musculoskeletal pain | 3 (19) | 58 (51) | 11 (44) |
Ageusia/anosmia | 7 (43) | 59 (52) | 3 (12) |
Asthenia | 1 (6) | 59 (52) | 8 (32) |
Cough | 0 (0) | 43 (38) | 23 (92) |
Dyspnoea | 0 (0) | 17 (15) | 25 (100) |
Pneumonia | 0 (0) | 3 (3) | 25 (100) |
Treatment | |||
Antibiotic | 0 (0) | 28 (25) | 25 (100) |
Hydroxychloroquine | 0 (0) | 12 (10) | 25 (75) |
Heparin | 0 (0) | 1 (1) | 24 (96) |
Antiviral | 0 (0) | 0 (0) | 8 (32) |
Monoclonal antibody | 0 (0) | 0 (0) | 4 (16) |
Steroids | 0 (0) | 14 (13) | 5 (20) |
NSAIDs | 0 (0) | 7 (6) | 0 (21) |
Paracetamol | 1 (6) | 20 (18) | 1 (4) |
*Oligosymptomatic patients are those with symptoms enduring for less than 3 days or with only one symptom (anosmia/ageusia or asthenia).
†Symptomatic patients are those with one more symptom lasting at least 3 days and without any hospital admission.
NSAIDs, Non-steroidal anti-inflammatory drugs.